(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual revenue growth rate of 41.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.03%.
Pelthos Therapeutics's revenue in 2026 is $43,304,000.On average, 9 Wall Street analysts forecast PTHS's revenue for 2026 to be $248,153,704, with the lowest PTHS revenue forecast at $209,237,316, and the highest PTHS revenue forecast at $289,876,359. On average, 9 Wall Street analysts forecast PTHS's revenue for 2027 to be $433,650,684, with the lowest PTHS revenue forecast at $380,434,965, and the highest PTHS revenue forecast at $482,387,094.
In 2027, PTHS is forecast to generate $437,134,590 in revenue, with the lowest revenue forecast at $284,922,320 and the highest revenue forecast at $557,118,809.